Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.

ABSTRACT:

Background

In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has shown survival benefit in multiple solid tumors. Based on previous research, this phase II clinical trial aims to verify apatinib's efficacy and safety in patients with advanced or recurrent cervical cancer.

Methods/design

This randomized, parallel arm, open-label, interventional trial will be carried out to evaluate the efficacy and the safety of apatinib for advanced or recurrent cervical cancer. A total of 60 eligible patients will be allocated by intention, in a ratio of 1:1, to ei

SUBMITTER: Zhou JG 

PROVIDER: S-EPMC6142681 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature